Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent expiration dates for Trulicity, Mounjaro, and other blockbuster medicines mean every Eli Lilly disclosure can shift expectations for future cash flow. If you have ever searched for Eli Lilly SEC filings explained simply, you know how dense a pharmaceutical 10-K can be. Stock Titan’s AI reads each document the instant it posts to EDGAR and serves a concise summary that highlights clinical-trial outcomes, FDA correspondence, and global pricing risks—turning hundreds of pages into a five-minute briefing.
Need details from the latest Eli Lilly quarterly earnings report 10-Q filing or a quick take on cash used for R&D? Our platform flags segment revenue, pipeline spend, and patent-life tables while linking directly to the full text. The annual report is here as the Eli Lilly annual report 10-K simplified; Form 8-K alerts keep you current with trial readouts and collaborations—see Eli Lilly 8-K material events explained. When proxy season arrives, the Eli Lilly proxy statement executive compensation section breaks down option awards, pay-for-performance metrics, and governance votes, all with clear AI commentary.
Monitoring insider sentiment? Track Eli Lilly insider trading Form 4 transactions and receive Eli Lilly Form 4 insider transactions real-time notifications. Our dashboards group every Eli Lilly executive stock transactions Form 4 with trend charts so you can spot buying or selling patterns before the market reacts. Use the built-in tools for Eli Lilly earnings report filing analysis or simply browse by form if you prefer traditional reading. Whether you’re comparing quarter-over-quarter margins or understanding Eli Lilly SEC documents with AI, this page delivers every filing, every update, in a workflow that saves hours and sharpens your investment decisions.
Daniel Skovronsky, EVP, Chief Scientific Officer and President of LRL & LLY Imm at Eli Lilly & Co (LLY), reported a purchase on 08/12/2025 of 1,000 shares of common stock on Form 4. The transaction is coded P for purchase at a weighted average price of $634.405 with execution prices ranging from $634.21 to $634.42. After the reported purchase the filing shows 137,660.112 shares beneficially owned directly. The filing also discloses indirect holdings of 72,359 shares by a trust, 747 shares by the reporting person’s spouse, and 2,510 shares held in a spousal lifetime access trust transferred on March 10, 2025. The filer disclaims beneficial ownership except to the extent of pecuniary interest.
Gabrielle Sulzberger, a director of Eli Lilly & Co. (LLY), reported acquiring 117 shares of common stock on 08/12/2025 under transaction code P. The reported price was $641.182 per share and her direct holdings after the trade were 2,703.055 shares. The Form 4 was filed by one reporting person.
On 08/12/2025, Director J. Erik Fyrwald reported purchases of Eli Lilly & Co. (LLY) common stock totaling 1,565 shares across two transactions: 686 shares at a weighted average price of $641.996 and 879 shares at $642.586. The Form 4 shows beneficial ownership rising to 73,698.779 shares after the first purchase and to 74,577.779 shares after the second. The filing notes the reported prices are weighted averages across multiple executions within disclosed price ranges and offers to provide detailed per-price execution data on request.
Ilya Yuffa, listed as EVP & President, LLY USA & Global Capab and an officer of Eli Lilly & Co., reported a sale of 1,250 shares of Eli Lilly common stock on 08/11/2025 at a reported price of $627.01 per share.
The Form 4 shows the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Following the reported transaction the form lists 26,259.971 shares beneficially owned by the reporting person in a direct ownership form. No derivative transactions are reported in Table II.
Jamere Jackson, identified as a Director of Eli Lilly & Co. (LLY), reported an acquisition of 200 shares of the company’s common stock on 08/08/2025 at a reported price of $639.563 per share. The Form 4 shows his ownership following the transaction as 9,401.724 shares, held directly.
Eli Lilly (LLY) posted another record quarter. Q2-25 revenue rose 38 % YoY to $15.56 bn, driven by cardiometabolic products (Mounjaro +68 % to $5.20 bn; first-year Zepbound $3.38 bn). Oncology added $2.41 bn (+12 %).
Profitability surged. Net income nearly doubled to $5.66 bn; diluted EPS jumped 92 % to $6.29. Six-month EPS is $9.35 (+62 %). Operating margin expanded as revenue growth outpaced increases in R&D (�23 %) and SG&A (�30 %). No special charges occurred this quarter versus $435 m last year.
Balance-sheet trends. Total assets grew to $100.9 bn (-year-end 24: $78.7 bn) mainly from higher receivables and a $3.4 bn inventory build to support GLP-1 demand. Debt increased to $39.9 bn (-year-end: $33.6 bn) after $6.46 bn of new issuances. Cash & equivalents held steady at $3.38 bn; operating cash flow more than doubled to $4.75 bn YTD.
Capital returns & pipeline. Dividend lifted to $3.00/sh (prior-year $2.60). $13.11 bn remains on the $15 bn buyback plan. Business development continues: closed $925 m Wisconsin injectables plant (May) and, post-quarter, announced up to $2.3 bn acquisitions of Verve (cardiovascular gene therapy) and SiteOne (pain).
Outlook signals. U.S. revenue accounted for 69 % of sales; Europe grew 83 % YoY. Management highlights demand but warns of pricing, manufacturing and regulatory risks. No updated guidance included in the excerpt.
Eli Lilly and Company filed a Form 8-K dated 7 Aug 2025 under Item 2.02 to furnish, not file, a press release (Ex. 99.1) that announces the company’s financial results for the quarter ended 30 Jun 2025. The actual earnings figures are not included in this submission; investors must review the accompanying press release for details. No other material transactions or disclosures are presented. The filing re-affirms the company’s NYSE listings for its common stock and various note issues and indicates that Lilly is not an emerging-growth company. The document is purely administrative and carries no immediate financial metrics or guidance.
Eli Lilly & Co. (LLY) filed a Form 144 notice for the proposed sale of restricted shares.
- Seller intends to dispose of 280,000 common shares through Fidelity Capital Markets.
- At the filing’s reference price, the block is worth $223.7 million.
- Eli Lilly has 947.7 million shares outstanding, so the sale represents roughly 0.03 % of the float—small in relation to daily liquidity and unlikely to be dilutive.
- Planned trade date: 24 Jul 2025; exchanges listed: NYSE / NASDAQ.
- The shares trace back to a 10 Feb 1948 gift from the J.K. Lilly Sr. Trust; no other sales were reported in the past three months.
The filer certifies awareness of no undisclosed material adverse information.
FAQ
What is the current stock price of Lilly Eli & Co (LLY)?
What is the market cap of Lilly Eli & Co (LLY)?
